La Croix R, Dostert P, Strolin Benedetti M
R&D/Pharmacokinetics and Metabolism Department, Pharmacia, SpA, Nerviano, Milan, Italy.
J Chromatogr B Biomed Appl. 1996 May 31;681(1):185-90. doi: 10.1016/0378-4347(95)00521-8.
A new sensitive high-performance liquid chromatographic (HPLC) method with fluorescence detection was developed for the determination of 2-phenylethylamine (PEA) in human urine. The analytical procedure involved a simple extraction of the analyte from urine, followed by precolumn derivatisation of the sample with o-phthalaldehyde. The HPLC separation was performed under isocratic conditions using an Erbasil S C18 (250 x 4.0 mm I.D., particle size 3 microns) reversed-phase column. The limit of quantitation was 0.5 ng of PEA/ml of urine. The method showed good linearity, accuracy and precision data in the concentration range 0.5-200 ng/ml of urine. The method was successfully applied to the determination of PEA urinary excretion in Parkinsonian patients after oral administration of the monoamine oxidase B (MAO-B) inhibitor, selegiline.
建立了一种新的灵敏的高效液相色谱（HPLC）荧光检测法，用于测定人尿中的2-苯乙胺（PEA）。分析步骤包括从尿液中简单提取分析物，然后用邻苯二甲醛对样品进行柱前衍生。HPLC分离在等度条件下进行，使用Erbasil S C18（内径250×4.0mm，粒径3微米）反相柱。定量限为0.5 ng PEA/毫升尿液。该方法在0.5-200 ng/毫升尿液的浓度范围内显示出良好的线性、准确度和精密度数据。该方法成功应用于帕金森病患者口服单胺氧化酶B（MAO-B）抑制剂司来吉兰后PEA尿排泄量的测定。
